Does overexpression of β-catenin and cyclinD1 predict a poor prognosis in ovarian serous carcinomas?
Expression of β-catenin and cyclinD1 may be used as predict markers for poor prognosis.
Our data suggest that the BSA-ABZ may hold promise for the treatment and control of progression of ovarian cancer with ascites. However further studies are required to examine the efficacy of both the formulations in aggressive models of recurrent ovarian cancer with respect to particle size and dosing parameters.